Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07361497 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 850
- Enrollment target
NCT07361497 is a Phase 3 study that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 850 participants.
The verdict
NCT07361497, a Phase 3 study, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 850 participants
- Enrollment target
Study Summary
A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
Interventions
- DRUG Pumitamig
- DRUG Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Start Date | 2026-03-16 |
| Est. Completion | 2033-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07361497
The ClinicalTrials.gov registry entry for NCT07361497 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 850 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pumitamig is the first listed.
NCT07361497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07361497 about?
NCT07361497 is a clinical study titled "A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)". A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
What is the current status of trial NCT07361497?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 850 participants. The study started on 2026-03-16. Estimated completion is 2033-12-31.
What interventions are being tested in trial NCT07361497?
The interventions under investigation include: Pumitamig (DRUG), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT07361497?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.